ARROWHEAD PHARMACEUTICALS, INC.
ARWRNasdaq
$74.30
↑ +4.1%Jul 17 close · end-of-day
Price
1Y↑ +306.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$10.6B
Enterprise Value
$9.0B
P/E
—
P/S
17.0
P/B
17.2
EV/EBITDA
—
PEG
—
FCF Yield
-0.5%
Dividend Yield
—
Revenue (TTM)
$622.0M
Net Income (TTM)
-$300.9M
Free Cash Flow (TTM)
-$50.9M
Gross Margin
—
Operating Margin
-35.7%
Net Margin
-48.4%
ROE
-49.0%
ROIC
—
Debt / Equity
—
Net Cash
$1.6B
Return 1Y
+294.2%
Company profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the. treatment of liver diseases associated with alpha-1 antitrypsin deficiency. ARO is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A.
- CEO
- Christopher R. Anzalone
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 400
- Headquarters
- California
- Website
- arrowheadpharma.com
Management & directors
- Hamilton James CChief Medical Officer
- Apel Daniel JosephChief Financial Officer
- O'Brien PatrickCOO
- Anzalone Christopher RichardChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
ARWR Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$73.7M↓ -86.4%
Diluted EPS-$0.93↓ -133.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $88.0M | $138.3M | $243.2M | $240.7M | $3.6M | $829.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$93.2M | -$149.0M | -$178.5M | -$205.0M | -$601.1M | $98.3M |
| Net income | -$84.6M | -$140.8M | -$176.1M | -$205.3M | -$599.5M | -$1.6M |
| Diluted EPS | -$0.84 | -$1.36 | -$1.67 | -$1.92 | -$5.00 | -$0.01 |
| Operating cash flow | -$95.8M | $171.3M | -$136.1M | -$153.9M | -$462.9M | $179.6M |
| Free cash flow | -$107.8M | $147.7M | -$188.9M | -$330.6M | -$604.3M | $156.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -105.9% | -107.8% | -73.4% | -85.2% | -16927.1% | 11.9% |
| Net margin | -96.1% | -101.9% | -72.4% | -85.3% | -16882.4% | -0.2% |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $2.5M | $542.7M | $27.8M | $256.5M | $264.0M | $73.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$176.1M | -$162.2M | -$161.4M | $381.2M | -$165.6M | $44.1M | $40.8M | -$141.3M |
| Net income | -$170.8M | -$170.5M | -$173.1M | $370.4M | -$175.2M | -$23.8M | $30.8M | -$132.7M |
| Diluted EPS | -$1.38 | -$1.36 | -$1.39 | $2.75 | -$1.26 | -$0.11 | $0.22 | -$0.93 |
| Operating cash flow | -$115.4M | -$137.2M | -$146.3M | $460.1M | -$154.7M | $20.5M | $13.5M | $84.4M |
| Free cash flow | -$129.9M | -$161.5M | -$153.8M | $454.8M | -$157.1M | $13.0M | $11.3M | $81.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | -6456.5% | 70.2% | -596.2% | 17.2% | 15.5% | -191.6% |
| Net margin | — | — | -6923.4% | 68.3% | -631.1% | -9.3% | 11.7% | -180.0% |
Company news
Jul 14, 2026
Jul 13, 2026
Jul 10, 2026
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | Cohen Matthew Gregory | Award | 11,882 | $0.00 | $0.00 | filing |
| 2026-05-12 | Lu Hongbo | Sale | 2,970 | $76.88 | $228,333.60 | filing |
| 2026-04-23 | Hamilton James C· Chief Medical Officer | Sale | 10,000 | $75.00 | $750,000.00 | filing |
| 2026-04-22 | Apel Daniel Joseph· Chief Financial Officer | Sale | 8,730 | $71.92 | $627,861.60 | filing |
| 2026-04-22 | Apel Daniel Joseph· Chief Financial Officer | Sale | 3,208 | $70.11 | $224,912.88 | filing |
| 2026-04-22 | Apel Daniel Joseph· Chief Financial Officer | Sale | 1,157 | $70.45 | $81,510.65 | filing |
| 2026-03-05 | Hamilton James C· Chief Medical Officer | Sale | 10,000 | $64.19 | $641,900.00 | filing |
| 2026-01-06 | O'Brien Patrick· COO | Award | 75,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | Apel Daniel Joseph· Chief Financial Officer | Award | 75,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | Hamilton James C· Chief Medical Officer | Award | 75,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | O'Brien Patrick· COO | Gift | 540 | $0.00 | $0.00 | filing |
| 2026-01-06 | O'Brien Patrick· COO | Gift | 540 | $0.00 | $0.00 | filing |
| 2026-01-06 | O'Brien Patrick· COO | Gift | 540 | $0.00 | $0.00 | filing |
| 2026-01-06 | O'Brien Patrick· COO | Gift | 440 | $0.00 | $0.00 | filing |
| 2026-01-06 | O'Brien Patrick· COO | Gift | 440 | $0.00 | $0.00 | filing |
| 2026-01-05 | Hamilton James C· Chief Medical Officer | Sale | 14,792 | $63.01 | $932,043.92 | filing |
| 2026-01-05 | O'Brien Patrick· COO | Sale | 13,451 | $62.96 | $846,874.96 | filing |
| 2026-01-05 | Hamilton James C· Chief Medical Officer | Sale | 12,711 | $63.95 | $812,868.45 | filing |
| 2026-01-05 | O'Brien Patrick· COO | Sale | 11,842 | $63.84 | $755,993.28 | filing |
| 2026-01-05 | O'Brien Patrick· COO | Sale | 6,164 | $62.23 | $383,585.72 | filing |
| 2026-01-05 | Hamilton James C· Chief Medical Officer | Sale | 6,090 | $62.28 | $379,285.20 | filing |
| 2026-01-05 | O'Brien Patrick· COO | Sale | 5,873 | $62.91 | $369,470.43 | filing |
| 2026-01-05 | Hamilton James C· Chief Medical Officer | Sale | 4,625 | $61.24 | $283,235.00 | filing |
| 2026-01-05 | O'Brien Patrick· COO | Sale | 4,368 | $61.20 | $267,321.60 | filing |
| 2026-01-05 | O'Brien Patrick· COO | Sale | 2,700 | $64.44 | $173,988.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.